Skip to content
WELCOME10 — 10% OFF YOUR FIRST ORDER  ·  FREE SHIPPING OVER $300 CAD  ·  COA ON EVERY ORDER

CJC-1295 (No DAC) vs Ipamorelin: What Is the Difference?

They are studied together far more than against each other — two different doors into the same growth-hormone release.

Shared research areas:Hormonal & EndocrineMetabolic

Overview

What CJC-1295 (No DAC) is

CJC-1295 without DAC (also called Modified GRF 1-29) is a trimmed, stabilised piece of the natural growth-hormone-releasing hormone that acts at the GHRH receptor to prompt short, natural GH pulses.

What Ipamorelin is

Ipamorelin is a small, selective peptide that acts at a different receptor — the ghrelin receptor — to release growth hormone while leaving stress and hunger signals mostly alone.

The difference, without the jargon

This is a pair people ask to compare, but the honest answer is that they are usually combined, not chosen between. Each reaches growth-hormone release through a separate receptor, so putting them together lets researchers study two non-overlapping pathways at once. In handling they are close: both dissolve in plain bacteriostatic water, both go in the fridge after mixing. The small difference is that CJC's coil will foam if you shake it, so it wants a gentle swirl, while Ipamorelin is about as forgiving as a peptide gets — no light or oxygen sensitivity at all.

Common questions

Should I pick one or the other?

In the research literature they are typically studied together precisely because their mechanisms are complementary — a GHRH-receptor pathway and a ghrelin-receptor pathway — rather than as substitutes.

Is CJC-1295 no DAC the same as Modified GRF 1-29?

Yes, they are two names for the same short-acting, tetra-substituted GHRH(1-29) peptide.

Why does CJC-1295 foam and Ipamorelin does not?

CJC has a longer, coil-shaped structure that gathers at the liquid surface when agitated; a gentle swirl avoids it. Ipamorelin is a short, rigid peptide with no such tendency.

Technical reference below

ClassGHRH(1-29) tetra-substituted analogue (DAC-free)Synthetic pentapeptide GH secretagogue (ghrelin-receptor agonist)
Molecular weight3367.9 g/mol711.85 g/mol
CAS numberNot assigned / not specifiedNot assigned / not specified
Purity spec≥99%≥97%
Research areasHormonal & Endocrine, MetabolicHormonal & Endocrine, Metabolic
Primary diluentBacteriostatic water (0.9% benzyl alcohol)Bacteriostatic water (0.9% benzyl alcohol)
Working windowCommonly worked with for 2-3 weeks at 2-8 °C.Commonly worked with for 3-4 weeks at 2-8 °C — helped by the absence of oxidation-prone residues.
Lead degradation routeDeamidation at Asn/Gln residues over long solution storage.C-terminal amide hydrolysis over long solution storage.
Freeze–thawAliquot on first reconstitution; avoid re-freezing the solution.Tolerates freezing reasonably; aliquot on first reconstitution as standard practice.
Light sensitivityNo specific light requirement beyond normal practice.No specific light requirement beyond normal practice.

How they actually differ

Two different doors to the same room. CJC-1295 without DAC works at the GHRH receptor, telling the pituitary to release growth hormone; Ipamorelin works at the ghrelin receptor to do the same thing through a separate pathway. Because the pathways do not overlap, research designs usually combine them rather than choose between them. In handling they are close cousins — both dissolve in plain water, both are refrigerated after mixing — though CJC's coil foams if shaken, while Ipamorelin is about as forgiving as peptides get.

CJC-1295 (No DAC) — origin

CJC-1295 without DAC is the first 29 residues of growth-hormone-releasing hormone carrying four stabilising substitutions (D-Ala2, Gln8, Ala15, Leu27) that resist DPP-4 cleavage. Omitting the Drug Affinity Complex — the albumin-binding element of the DAC version — gives it a short half-life, which is the property researchers study it for.

Ipamorelin — origin

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a pentapeptide ghrelin-receptor agonist. It was characterised as the first highly selective growth-hormone secretagogue — prompting GH release with minimal effect on cortisol, prolactin or appetite signalling, which is the property that keeps it in the research literature.

CJC-1295 (No DAC) research themes

Pulsatile GH release

Studied for prompting growth-hormone release in short, physiological pulses via the GHRH receptor.

DPP-4 resistance

The four substitutions are studied for extending the molecule beyond the minutes-long survival of native GHRH.

Complementary pairing

Frequently studied alongside ghrelin-receptor secretagogues such as Ipamorelin, which recruit a second GH-release pathway.

Ipamorelin research themes

Ghrelin-receptor selectivity

Studied as a selective GHS-R agonist that releases GH with little effect on cortisol, prolactin or ACTH — the feature that distinguishes it from earlier GHRPs.

GH pulsatility

Examined for the shape and timing of growth-hormone release in research models.

Complementary pairing

Frequently combined with GHRH analogues such as CJC-1295 to study two GH-release pathways at once.

CJC-1295 (No DAC) handling

  • Reach room temperature before opening.
  • Swirl to dissolve; do not shake or vortex — foam indicates interfacial stress on the helix.
  • Aliquot and refrigerate; never re-freeze reconstituted solution.

Ipamorelin handling

  • Reach room temperature before opening.
  • Swirl to dissolve; the peptide clears in seconds.
  • Label aliquots with reconstitution date and diluent.

Both third-party tested

Every Popular Peptides batch of CJC-1295 (No DAC) and Ipamorelin is independently tested by HPLC and LC-MS with a published Certificate of Analysis. Enter a lot number to pull the COA for a specific vial.

CJC-1295 (No DAC) reference

Ipamorelin reference

Related comparisons

CJC-1295 (No DAC) and Ipamorelin are supplied strictly as research chemicals for in-vitro laboratory and research use only. They are not intended for human or animal consumption, diagnostic, or therapeutic use. This comparison summarizes published preclinical literature and laboratory handling data; it is not medical advice, not a claim of efficacy, and not usage guidance.